(2R)-2-benzyl-3-(morpholinocarbonyl)propionic acid | 112804-14-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: (2R)-2-benzyl-3-(morpholinocarbonyl)propionic acid
• 英文别名: 2(R)-2-<(4-morpholinylcarbonyl)methyl>-3-phenylpropionic acid；2-(R)-benzyl-3-morpholinocarbonyl propionic acid；(R)-2-benzyl-3-(morpholinocarbonyl)propionic acid；3-(morpholin-4-yl)carbonyl-2(R)-benzylpropionic acid；(R)-gamma-oxo-alpha-(phenylmethyl)-4-morpholinebutyric acid；(2 R)-2-benzyl-4-morpholino-4-oxobutyric acid；2(R)-benzyl-3-(morpholinocarbonyl)propionic acid；(2R)-2-benzyl-4-morpholin-4-yl-4-oxobutanoic acid
• CAS: 112804-14-5
• 化学式: C₁₅H₁₉NO₄
• 分子量: 277.32
• InChiKey: OWRXCPCLQZZRJO-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2R)-2-benzyl-3-(morpholinocarbonyl)propionic acid 、 H-histidine amide of (1'R,2'S,5S)-5-(2'-amino-3'-cyclohexyl-1'-hydroxypropyl)-3-ethyloxazolidin-2-one 在 N-甲基吗啉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (R)-2-Benzyl-N-[(S)-1-[(1S,2R)-1-cyclohexylmethyl-2-((S)-3-ethyl-2-oxo-oxazolidin-5-yl)-2-hydroxy-ethylcarbamoyl]-2-(3H-imidazol-4-yl)-ethyl]-4-morpholin-4-yl-4-oxo-butyramide
  参考文献：
  名称：

  Water-soluble renin inhibitors: design of a subnanomolar inhibitor with a prolonged duration of action

  摘要：

  Incorporation of nonreactive polar functionalities at the C- and N-termini of renin inhibitors led to the development of a subnanomolar compound (21) with millimolar solubility. This inhibitor demonstrated excellent efficacy and a long duration of action upon intravenous administration to monkeys. While activity was also observed intraduodenally, a comparison of the blood pressure responses indicated low bioavailability. Subsequent experiments in rats showed that, although the compound was absorbed from the gastrointestinal tract, extensive liver extraction severely limited bioavailability.

  DOI：

  10.1021/jm00169a024
• 作为产物：
  描述：

  (4S)-3-(3-phenylpropionyl)-4-(2-propyl)oxazolidin-2-one 在 palladium on activated charcoal N-甲基吗啉 、 正丁基锂 、 氢气 、 sodium hexamethyldisilazane 、 三氟乙酸 、 氯甲酸异丁酯 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙酸乙酯 为溶剂， -78.0~25.0 ℃ 、101.33 kPa 条件下， 反应 8.58h， 生成 (2R)-2-benzyl-3-(morpholinocarbonyl)propionic acid
  参考文献：
  名称：

  Renin inhibitors. Dipeptide analogs of angiotensinogen utilizing a structurally modified phenylalanine residue to impart proteolytic stability

  摘要：

  A series of renin inhibitors have been prepared and evaluated for their susceptibility to cleavage by the serine protease chymotrypsin. The compounds were designed by consideration of the structural requirements in the active-site region of renin and chymotrypsin. By systematic alteration of the P3 phenylalanine residue, compounds with varying degrees of renin inhibitory potency and chymotrypsin susceptibility were obtained. Selected analogues from this group were examined in vivo for both their hypotensive effects and metabolic patterns.

  DOI：

  10.1021/jm00120a006

文献信息

• Renin inhibitors containing a pyridyl amino diol derived C-terminus
  作者：Holger Heitsch、Rainer Henning、Heinz Werner Kleemann、Wolfgang Linz、Wolf Ulrich Nickel、Dieter Ruppert、Hansjoerg Urbach、Adalbert Wagner

  DOI：10.1021/jm00071a009

  日期：1993.9

  the concept of transition-state analogs, a series of nonpeptide renin inhibitors with the new (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-(2-pyridyl)hexane moiety at the C-terminal functionality were synthesized and evaluated for inhibition of renin both in vitro and in vivo. All compounds exhibited potencies in the nanomolar or even subnanomolar range when tested versus human renin in vitro. Selected

  基于过渡态类似物的概念，一系列具有新的（2S，3R，4S）-2-氨基-1-环己基-3,4-二羟基-6-（2-吡啶基）己烷部分的非肽肾素抑制剂合成了在C-末端的C末端功能，并在体外和体内评估了对肾素的抑制。当与人肾素进行体外测试时，所有化合物均显示出纳摩尔或什至亚纳摩尔范围的效力。在麻醉的，钠缺乏的恒河猴中评估选定的抑制剂，并在十二指肠内给予2 mg / kg的剂量后，平均动脉血压（MAP）明显降低。含有氨基哌啶基琥珀酸衍生的N端的化合物38（S 2864）是该系列中最有希望的成员。38种抑制人肾素的IC50为0.38 nM，不影响其他人天冬氨酸蛋白酶，
• Renin inhibitors
  申请人：American Cyanamid Company

  公开号：US05104869A1

  公开（公告）日：1992-04-14

  Renin inhibiting compounds containing a single .alpha.-amino acid of the formula: ##STR1## and analogs thereof which inhibit the substrate-cleaving acting or renin, pharmaceutical compositions containing these compounds, processes for producing the compounds and methods of treating hypertension which employ the novel renin inhibitors.

  含有单个α-氨基酸的抑制肾素化合物的翻译：##STR1##及其类似物，这些化合物抑制肾素的底物裂解作用，含有这些化合物的药物组合物，生产这些化合物的方法以及使用新型肾素抑制剂治疗高血压的方法。
• Renin-inhibiting functionalized peptidyl aminodiols and - triols
  申请人：ABBOTT LABORATORIES

  公开号：EP0341602A2

  公开（公告）日：1989-11-15

  A renin inhibiting compound of the formula: or a pharmaceutically acceptable salt, ester or prodrug thereof.

  一个公式为的抑制肾素的化合物： 或其药用可接受的盐、酯或前药。
• Modular 1,1′-Ferrocenediyl-cored <i>P</i> -Stereogenic Diphosphines: ′′JDayPhos′′ Series and its Use in Rhodium(I)-Catalyzed Hydrogenation
  作者：Gašper Poklukar、Michel Stephan、Barbara Mohar

  DOI：10.1002/adsc.201800255

  日期：2018.7.4

  A novel ferrocene‐based P‐stereogenic diphospine ligand series dubbed JDayPhos was developed, which rhodium(I) complexes of some of its members exhibited excellent enantioselectivity (up to >99% ee) and high activity in asymmetric hydrogenation of β‐unsubstituted or ‐substituted itaconates and α‐methylene‐γ‐oxo‐carboxylates.

  开发了一种新型的基于二茂铁的P-立体异构二膦配体系列JDayPhos，该化合物的一些成员的铑（I）配合物表现出出色的对映选择性（高达> 99％ee），并且在β-未取代或-β的不对称氢化中表现出高活性。取代的衣康酸酯和α-亚甲基-γ-氧代羧酸酯。
• Peptidyl difluorodiol renin inhibitors
  申请人：ABBOTT LABORATORIES

  公开号：EP0416393A1

  公开（公告）日：1991-03-13

  A renin inhibiting compound of the formula: wherein A is a functional group; W is (1) -C(O)-, (2) -CH(OH)- or (3) -N(R₂)- wherein R₂ is hydrogen or loweralkyl; U is (1) -C(O)-, (2) -CH₂- or (3) -N(R₂)- wherein R₂ is hydrogen or lower alkyl, with the proviso that when W is -CH(OH)- then U is -CH₂- and with the proviso that U is -C(O)- or -CH₂- when W is -N(R₂)-; V is (1) -CH-, (2) -C(OH)- or (3) -C(halogen)- with the proviso that v is -CH-­when U is -N(R₂)-; Q is -CH(R₁)- or -C(=CHR1a)- wherein R₁ is (1) loweralkyl, (2) cycloalkylalkyl, (3) arylalkyl, (4) (heterocyclic)alkyl, (5) 1-benzyloxyethyl, (6) phenoxy, (7) thiophenoxy or (8) anilino, provided that B is -CH₂- or -CH(OH)- or A is hydrogen when R₁ is phenoxy, thiophenoxy or anilino and R1a is aryl or heterocyclic; R₃ is a functional group; R₄ is (1) loweralkyl, (2) cycloalkylmethyl or (3) benzyl; R₅ is -CH(OH)- or -C(O)-; R₆ is -CH(OH)- or -C(O)-; and Z is (1) lower alkyl, (2) aryl, (3) arylalkyl, (4) cycloalkyl, (5) cycloalkylalkyl, (6) heterocyclic or (7) (heterocyclic)alkyl; or a pharmaceutically acceptable salt, ester or prodrug thereof.

  一种肾素抑制化合物的化学式：其中A是一个功能基团；W是(1) -C(O)-，(2) -CH(OH)-或(3) -N(R₂)-，其中R₂是氢或较低烷基；U是(1) -C(O)-，(2) -CH₂-或(3) -N(R₂)-，其中R₂是氢或较低烷基，但当W为-CH(OH)-时，则U为-CH₂-，并且当U为-N(R₂)-时，U为-C(O)-或-CH₂-；V是(1) -CH-，(2) -C(OH)-或(3) -C(卤素)-，但当U为-N(R₂)-时，V为-CH-；Q是-CH(R₁)-或-C(=CHR1a)-，其中R₁是(1) 较低烷基，(2) 环烷基烷基，(3) 芳基烷基，(4) (杂环)烷基，(5) 1-苄氧乙基，(6) 苯氧基，(7) 噻吩氧基或(8) 氨基苯基，前提是当R₁是苯氧基、噻吩氧基或氨基苯基时，B是-CH₂-或-CH(OH)-，或A是氢，而R1a是芳基或杂环；R₃是一个功能基团；R₄是(1) 较低烷基，(2) 环烷基甲基或(3) 苄基；R₅是-CH(OH)-或-C(O)-；R₆是-CH(OH)-或-C(O)-；Z是(1) 较低烷基，(2) 芳基，(3) 芳基烷基，(4) 环烷基，(5) 环烷基烷基，(6) 杂环或(7) (杂环)烷基；或其药学上可接受的盐、酯或前药。